Castle biosciences' decisiondx®-scc data earns top five abstract at nccn 2025, shows significantly enhanced risk stratification beyond current staging within nccn risk groups

New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (scc) demonstrates that the addition of decisiondx-scc to brigham & women's hospital (bwh) staging significantly refines metastatic risk prediction in patients classified as high-risk and very high-risk by national comprehensive cancer network (nccn) guidelines to support improved, risk-aligned treatment pathway decisions castle will also present new data showing decisiondx®-melanoma as a significant predictor of mortality in a real-world cohort of nearly 7,000 patients with early-stage cutaneous melanoma (cm), reinforcing its value in identifying patients who may benefit from treatment plan strategies to improve outcomes friendswood, texas, march 28, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, will share new data on its risk-stratification tests for patients with skin cancers, decisiondx-scc and decisiondx-melanoma, via two poster presentations at the nccn 2025 annual conference, being held march 28-30 in orlando, florida. as a top five, blue-ribbon abstract at the conference, castle's poster on decisiondx-scc will also be shared in a special oral presentation with the other top-scoring submissions.
CSTL Ratings Summary
CSTL Quant Ranking